Free tool
Oncology stocks
We cover 5 companies grouped under the Oncology theme. The median market value in the group is $26.29B. Across the group, the median move over the past trading day is +1.36%. Price change over the past year runs from −9.8% to +316.8% across the middle 80 percent of the group, with a median of +49.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.